Press Release: Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
London, UK – 13th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that results from its Phase 1 pharmacokinetic (PK), pharmacodynamic (PD) and bioavailability study of S-pindolol benzoate (ACM-001.1) in healthy volunteers (NCT06028321)…
Press Release: Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle - Newscast
Mon, 31 Mar 2025 17:00:00 GMT 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that ...
Tue, 25 Mar 2025 15:24:00 GMT BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics ... acted as sole placement agent for the offering. This press release shall not constitute an offer to sell or the solicitation ...
Sun, 23 Mar 2025 17:01:00 GMT ThinkEquity is acting as the exclusive placement agent for the offering. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale ...
